journal article·2025-02-18Open access

Apolipoprotein Fusion Enables Spontaneous Functionalization of mRNA Lipid Nanoparticles with Antibody for Targeted Cancer Therapy

Wonbeom Park, Jiwoong Choi, Jaehyeon Hwang, Suhyun Kim, Yelee Kim, Man Kyu Shim, Wooram Park, Seokhyeon Yu, Sangwon Jung, Yoosoo Yang, Dae-Hyuk Kweon

ACS Nano· Volume 19· Issue 6

Abstract

The mRNA-lipid nanoparticles (mRNA@LNPs) offer a novel opportunity to treat targets previously considered undruggable. Although antibody conjugation is crucial for enhancing the specificity, delivery efficiency, and minimizing the toxicity of mRNA therapeutics, current chemical conjugation methods are complex and produce heterogeneous particles with misoriented antibodies. In this work, we introduce a chemical-free approach to functionalize mRNA@LNPs with antibodies, mimicking protein corona formation for targeted mRNA delivery. By fusing apolipoprotein to the Fc domain of a targeting antibody, we enabled the antibody to spontaneously display on the surface of mRNA@LNPs without altering the existing LNP process or employing complex chemical conjugation techniques. We demonstrated precise protein expression using trastuzumab-bound mRNA@LNPs, facilitating specific mRNA expression in HER2-positive cancer cells. mRNA was efficiently delivered to the tumor site after intravenous administration. While the control LNPs lacking targeting antibodies caused acute liver toxicity, trastuzumab-displayed LNPs showed no systemic toxicity. The tumor-specific delivery of p53 tumor suppressor mRNA led to the complete regression of cancer cells. Thus, apolipoprotein fusion enables a straightforward and scalable production of antibody-functionalized mRNA@LNPs, offering significant therapeutic potential in gene therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Monoclonal and Polyclonal Antibodies Research · RNA Interference and Gene Delivery · RNA Research and Splicing

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Integrative Biotechnology

Sungkyunkwan University

Biomedical Research Division

Korea Institute of Science and Technology (KIST)

Department of Life Sciences

Korea University

Research Center

MVRIX

Division of Bio-Medical Science and Technology, KIST School

Korea University of Science and Technology

Funding

Ministry of Science and ICT, South Korea

References (61)

Show source-provided references
1. 10.1038/s41568-023-00586-210.1038/s41568-023-00586-2 ↗
2. 10.1038/s41392-022-01007-w10.1038/s41392-022-01007-w ↗
3. 10.1186/s12943-023-01807-w10.1186/s12943-023-01807-w ↗
4. 10.1038/s41591-022-02061-110.1038/s41591-022-02061-1 ↗
5. 10.1038/s41578-021-00358-010.1038/s41578-021-00358-0 ↗
6. 10.1038/s41573-021-00283-510.1038/s41573-021-00283-5 ↗
7. 10.1038/nature2300310.1038/nature23003 ↗
8. 10.1155/2018/432587410.1155/2018/4325874 ↗
9. 10.1038/s41392-023-01674-310.1038/s41392-023-01674-3 ↗
10. 10.1038/s41586-023-06063-y10.1038/s41586-023-06063-y ↗
11. 10.1126/scitranslmed.abc780410.1126/scitranslmed.abc7804 ↗
12. 10.18632/oncotarget.246310.18632/oncotarget.2463 ↗
13. 10.1038/s41467-022-28279-810.1038/s41467-022-28279-8 ↗
14. 10.1038/s41551-018-0284-010.1038/s41551-018-0284-0 ↗
15. 10.1126/scitranslmed.aba977210.1126/scitranslmed.aba9772 ↗
16. 10.1038/s41576-021-00439-410.1038/s41576-021-00439-4 ↗
17. 10.1038/nrd427810.1038/nrd4278 ↗
18. 10.1186/s12951-022-01478-710.1186/s12951-022-01478-7 ↗
19. 10.1016/j.cell.2009.01.01910.1016/j.cell.2009.01.019 ↗
20. 10.1038/s41571-023-00811-910.1038/s41571-023-00811-9 ↗
21. 10.1016/j.addr.2023.11499010.1016/j.addr.2023.114990 ↗
22. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
23. 10.1016/j.mtadv.2022.10029910.1016/j.mtadv.2022.100299 ↗
24. 10.1126/science.abm059410.1126/science.abm0594 ↗
25. 10.1016/j.jconrel.2024.05.03610.1016/j.jconrel.2024.05.036 ↗
26. 10.1016/j.ymthe.2021.06.00410.1016/j.ymthe.2021.06.004 ↗
27. 10.1126/science.ade696710.1126/science.ade6967 ↗
28. 10.1126/sciadv.abc945010.1126/sciadv.abc9450 ↗
29. 10.3762/bjnano.14.7510.3762/bjnano.14.75 ↗
30. 10.1016/j.ab.2007.10.02210.1016/j.ab.2007.10.022 ↗
31. 10.3390/pharmaceutics1209080210.3390/pharmaceutics12090802 ↗
32. 10.1021/mp500400k10.1021/mp500400k ↗
33. 10.1038/s41565-017-0043-510.1038/s41565-017-0043-5 ↗
34. 10.1038/s41467-018-06936-110.1038/s41467-018-06936-1 ↗
35. 10.1016/j.biotechadv.2011.09.01310.1016/j.biotechadv.2011.09.013 ↗
36. 10.1038/nnano.2013.18110.1038/nnano.2013.181 ↗
37. 10.1021/acsnano.5b0752210.1021/acsnano.5b07522 ↗
38. 10.1016/0005-2760(76)90282-410.1016/0005-2760(76)90282-4 ↗
39. 10.1039/c4nr02793k10.1039/c4nr02793k ↗
40. 10.1021/ja107583h10.1021/ja107583h ↗
41. 10.1038/srep0502010.1038/srep05020 ↗
42. 10.1016/j.nano.2024.10273210.1016/j.nano.2024.102732 ↗
43. 10.1038/s43018-024-00796-z10.1038/s43018-024-00796-z ↗
44. 10.1038/s41573-022-00571-810.1038/s41573-022-00571-8 ↗
45. 10.1016/S0092-8674(00)81871-110.1016/S0092-8674(00)81871-1 ↗
46. 10.1038/s41418-018-0246-910.1038/s41418-018-0246-9 ↗
47. 10.1126/science.379810610.1126/science.3798106 ↗
48. 10.1016/j.ctrv.2006.01.00110.1016/j.ctrv.2006.01.001 ↗
49. 10.1002/advs.20230991710.1002/advs.202309917 ↗
50. 10.1002/adma.20210635010.1002/adma.202106350 ↗
51. 10.3389/fphar.2022.85696110.3389/fphar.2022.856961 ↗
52. 10.3389/fimmu.2023.109089810.3389/fimmu.2023.1090898 ↗
53. 10.3390/cimb4410034110.3390/cimb44100341 ↗
54. 10.1007/s13346-013-0158-710.1007/s13346-013-0158-7 ↗
55. 10.1038/nnano.2010.16410.1038/nnano.2010.164 ↗
56. 10.1016/j.jconrel.2024.02.02010.1016/j.jconrel.2024.02.020 ↗
57. 10.1038/s41578-023-00552-210.1038/s41578-023-00552-2 ↗
58. 10.1038/nnano.2012.23710.1038/nnano.2012.237 ↗
59. 10.1021/acsnano.5b0330010.1021/acsnano.5b03300 ↗
60. 10.1038/s41467-022-31882-410.1038/s41467-022-31882-4 ↗
61. 10.3389/fbioe.2020.0016610.3389/fbioe.2020.00166 ↗